Bipolar Disorder Mood Stabilizers Market, By Drug Type, By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Geography

Description

The Global Bipolar Disorder Mood Stabilizers Market is estimated to be valued at USD 2.22 Bn in 2025 and is expected to reach USD 2.64 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 2.5% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 2.22 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	2.50%	2032 Value Projection:	USD 2.64 Bn

Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Mood stabilizers are a class of drugs used to prevent or treat the extreme mood swings associated with bipolar disorder. The global bipolar disorder mood stabilizers market has been gaining significant traction over the past few years, owing to the rising prevalence of bipolar disorder worldwide and growing awareness regarding its effective treatment options. Increasing R&D investments by pharmaceutical companies to develop novel treatment alternatives are also propelling the market growth.

Market Dynamics

The global bipolar disorder mood stabilizers market is primarily driven by the growing prevalence of bipolar disorder caused by genetic and environmental factors such as traumatic life events and substance abuse. As per WHO statistics released in July 2024, over 45 million people worldwide suffer from bipolar disorder. Furthermore, rising awareness about available treatment options and increased healthcare spending are encouraging more patients to seek medical help. Meanwhile, continuous innovations and introduction of new drug formulations with higher efficacy and improved tolerability are helping expand the market reach. However, the market potential is still untapped in underdeveloped economies due to low diagnosis and treatment rates of mental disorders. High costs of branded drugs also limit their adoption in price-sensitive markets. Nonetheless, ongoing clinical trials for advanced drugs, especially for treatment-resistant patients, are expected to introduce new opportunities during the forecast period.

Key Features of the Study

This report provides in-depth analysis of the global bipolar disorder mood stabilizers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bipolar disorder mood stabilizers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, GlaxoSmithKline, Sanofi S.A., Merck & Co., Teva Pharmaceutical Industries, Novartis AG, Otsuka Pharmaceutical, H. Lundbeck A/S, Takeda Pharmaceutical Company, and Alkermes plc
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bipolar disorder mood stabilizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder mood stabilizers market

Market Segmentation

Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Lithium
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- Others (Combination Therapies, etc.)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
- Mixed Features Bipolar Disorder
- Rapid Cycling Bipolar Disorder
- Others
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral/Injectable
- Transdermal
- Others
Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Children and adolescents
- Adults
- Elderly
- Gender
- Male
- Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Eli Lilly and Company
- AstraZeneca PLC
- Johnson & Johnson
- Pfizer Inc.
- AbbVie Inc.
- Bristol-Myers Squibb
- GlaxoSmithKline
- Sanofi S.A.
- Merck & Co.
- Teva Pharmaceutical Industries
- Novartis AG
- Otsuka Pharmaceutical
- Lundbeck A/S
- Takeda Pharmaceutical Company
- Alkermes plc

Product Code: CMI7877

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Bipolar Disorder Mood Stabilizers Market, By Drug Type
- Global Bipolar Disorder Mood Stabilizers Market, By Indication
- Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration
- Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics
- Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel
- Global Bipolar Disorder Mood Stabilizers Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Bipolar Disorder Mood Stabilizers Market, By Drug Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Lithium
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lithium Carbonate
Lithium Citrate
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Valproic Acid/Valproate/Divalproex Sodium
Lamotrigine
Carbamazepine
Oxcarbazepine
Topiramate
Atypical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Aripiprazole
Olanzapine
Quetiapine
Risperidone
Lurasidone
Ziprasidone
Asenapine
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Combination Therapies, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Bipolar Disorder Mood Stabilizers Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Bipolar I Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar II Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cyclothymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Mixed Features Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rapid Cycling Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral/Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Children and adolescents
Adults
Elderly
Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Male
Female

8. Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Bipolar Disorder Mood Stabilizers Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alkermes plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

11. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

12. References and Research Methodology

References
Research Methodology
About us